• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Senseonics Holdings Inc.

    5/20/26 4:51:58 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care
    Get the next $SENS alert in real time by email
    S-8 1 tm2615158d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 20, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Senseonics Holdings, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware 47-1210911
    (State or other jurisdiction of Incorporation or
    organization)
    (I.R.S. Employer Identification No.)

     

    20451 Seneca Meadows Parkway

    Germantown, MD 20876-7005

    (Address of principal executive offices) (Zip code)

     

    2026 Equity Incentive Plan

    2016 Employee Stock Purchase Plan

    Amended and Restated 2015 Equity Incentive Plan

    (Full title of the plan)

     

    Timothy T. Goodnow

    President and Chief Executive Officer

    Senseonics Holdings, Inc.

    20451 Seneca Meadows Parkway

    Germantown, MD 20876-7005

    (301) 515-7260

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Darren K. DeStefano
    Reid S. Hooper
    Cooley LLP
    11951 Freedom Drive
    Reston, VA 20190
    (703) 456-8000
    Rick Sullivan
    Chief Financial Officer
    Senseonics Holdings, Inc.
    20451 Seneca Meadows Parkway
    Germantown, MD 20876-7005
    (301) 515-7260

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an aggregate of up to 8,802,296 shares of common stock, par value $0.001 per share (the “Common Stock”), of Senseonics Holdings, Inc. (the “Registrant”). The shares being registered consist of: (i) 1,444,302 shares of Common Stock issuable pursuant to the Registrant’s Amended and Restated 2015 Equity Incentive Plan (the “2015 Plan”), (ii) 412,658 shares of Common Stock issuable pursuant to the Registrant’s 2016 Employee Stock Purchase Plan (the “2016 ESPP”) and (iii) up to 6,945,336 shares of Common Stock issuable pursuant to the Registrant’s 2026 Equity Incentive Plan (the “2026 Plan” and, collectively with the 2015 Plan and 2016 Plan, the “Plans”).

     

    The 2026 Plan was adopted by the Registrant’s Board of Directors on March 25, 2026, subject to stockholder approval, which was obtained at the Annual Meeting of Stockholders (the “2026 Annual Meeting”) on May 20, 2026 (the “Effective Date”). The up to 6,945,336 shares of Common Stock registered hereby for issuance under the 2026 Plan consist of: (i) 1,300,000 shares of Common Stock that were authorized for issuance under the 2026 Plan by the Registrant's stockholders at the 2026 Annual Meeting; (ii) 413,148 shares that rolled into the 2026 Plan from the unallocated share reserves of the Company’s 2023 Commercial Equity Plan (the “2023 Plan”) and the 2015 Plan (the 2023 Plan and 2015 Plan, together, the “Prior Plans”); (iii) up to 5,232,188 shares of Common Stock subject to outstanding equity awards previously granted under the 2023 Plan and the 2015 Plan that, pursuant to the terms of the 2026 Plan, may become available for future grant under the 2026 Plan to the extent that such awards expire, terminate, are cancelled or forfeited, or are settled in cash in lieu of shares, without the issuance of shares of Common Stock thereunder. No new awards will be granted under the Prior Plans on or after the Effective Date, and all outstanding awards previously granted under the Prior Plans will remain outstanding, subject to the terms thereof.

     

    The 1,444,302 additional shares of Common Stock registered hereby for issuance pursuant to the 2015 Plan and the 412,658 additional shares of Common Stock registered hereby for issuance pursuant to the 2016 ESPP represent shares that have been reserved for issuance pursuant to the “evergreen” provision of the 2015 Plan and the 2016 ESPP, respectively, which provide for an automatic annual increase in the total number of shares reserved under each plan pursuant to a specified formula. These additional shares of Common Stock are securities of the same class as other securities for which an original registration statement on Form S-8 (File No. 333-210586) was filed with the Securities and Exchange Commission (the “Commission”) on April 4, 2016. 

     

    Accordingly, pursuant to General Instruction E of Form S-8, the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on April 4, 2016 (File No. 333-210586), May 10, 2018 (File No. 333-224827), May 9, 2019 (File No. 333-231334), May 26, 2022 (File No. 333-265241) and August 6, 2025 (File No. 333-289309), and the Registrant's registration statement on Form S-3 filed with the Commission on January 10, 2023 (File No. 333-269177), are incorporated by reference into this Registration Statement.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    ITEM 1. PLAN INFORMATION.

     

    The documents containing the information specified in Part I is omitted from this Registration Statement and included in documents sent or given to participants in the 2026 Plan in accordance with Rule 428(b) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be, and are not, filed with the Commission, either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference under this Registration Statement pursuant to Item 3 of Part II of the Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

     

     

    ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION.

     

    The written statement required by Item 2 of Part I is omitted from this Registration Statement and included in documents that sent or given to participants in the plans covered by this Registration Statement pursuant to Rule 428(b) of the Securities Act.

     

    PART II

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The Registrant is subject to the informational and reporting requirements of Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports and other information with the Commission. The following documents filed by the Registrant with the Commission pursuant to the Exchange Act are incorporated by reference in this Registration Statement:

     

      (a)  The Registrant’s Annual Report on Form 10-K (File No. 001-37717) for the fiscal year ended December 31, 2025, filed with the Commission on March 2, 2026;

     

      (b)  The Registrant’s Definitive Proxy Statement on Schedule 14A for the 2026 Annual Meeting (File No. 001-37717) filed with the Commission on April 6, 2026 (the “Proxy Statement”), as amended by that certain Amendment No. 1 to the Proxy Statement (File No. 001-37717) filed with the Commission on April 9, 2026;

     

      (c)  The Registrant’s Quarterly Report on Form 10-Q (File No. 001-37717) for the fiscal quarter ended March 31, 2026, filed with the Commission on May 7, 2026;

     

      (d)  The Registrant’s Current Reports on Form 8-K (File No. 001-37717) filed with the Commission on January 2, 2026, January 12, 2026 (excluding item 2.02), March 12, 2026, May 1, 2026 (excluding items 2.02 and 7.01), and May 4, 2026 and May 20, 2026; and

     

      (e)  The Registrant’s description of its common stock filed as Exhibit 4.3 to its Annual Report on Form 10-K (File No. 001-37717) for the fiscal year ended December 31, 2025, filed with the Commission on March 2, 2026, including any amendment or report filed for the purpose of updating such description.

     

    All documents, reports and definitive proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than current reports furnished under Item 2.02 and Item 7.01 of Form 8-K and exhibits filed with such form that are related to such items) after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

     

     

     

    ITEM 8. EXHIBITS

     

    Exhibit
    Number
      Description
    4.1(1)   Amended and Restated Certificate of Incorporation, as currently in effect.
    4.2(2)   Certificate of Amendment to Amended and Restated Certificate of Incorporation.
    4.3(3)   Certificate of Amendment to Amended and Restated Certificate of Incorporation.
    4.4(4)   Certificate of Amendment to Amended and Restated Certificate of Incorporation.
    4.5(5)   Certificate of Amendment to Amended and Restated Certificate of Incorporation.
    4.6(6)   Amended and Restated Bylaws, as currently in effect.
    4.7(7)   Amendment to Bylaws.
    4.8(8)   Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock.
    4.9(9)   Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock.
    4.10(10)   Specimen stock certificate evidencing shares of Common Stock.
    4.11(11)   2016 Employee Stock Purchase Plan.
    4.12 (12)   Amended and Restated 2015 Equity Incentive Plan
    4.13 (13)   Form of Stock Option Grant Notice and Stock Option Agreement under Amended and Restated 2015 Equity Incentive Plan.
    4.14(14)   Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under Amended and Restated 2015 Equity Incentive Plan.
    4.15   2026 Equity Incentive Plan.
    4.16   Form of Stock Option Grant Notice and Stock Option Agreement under 2026 Equity Incentive Plan.
    4.17   Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2026 Equity Incentive Plan.
    5.1   Opinion of Cooley LLP.
    23.1   Consent of KPMG LLP, independent registered public accounting firm.
    23.2   Consent of Cooley LLP (included in Exhibit 5.1).
    24.1   Power of Attorney (included on the signature page of this Form S-8).
    107   Filing Fee Table.

     

     

    (1) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on March 23, 2016, and incorporated by reference herein.

    (2) Previously filed as Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2018 (File No. 001-37717), filed with the Commission on August 8, 2018, and incorporated by reference herein.

    (3) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on October 26, 2020, and incorporated by reference herein.

    (4) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on May 22, 2024, and incorporated by reference herein.

    (5) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on October 16, 2025, and incorporated by reference herein.

    (6) Previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on March 23, 2016, and incorporated by reference herein.

    (7) Previously filed as Exhibit 3.7 to the Registrant’s Annual Report on Form 10-K (File No. 001-37717), filed with the Commission on March 5, 2021, and incorporated by reference herein.

    (8) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on August 18, 2020, and incorporated by reference herein.

    (9) Previously filed as Exhibit 3.5 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37717), filed with the Commission on November 8, 2022, and incorporated by reference herein.

    (10) Previously filed as Exhibit 4.2 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208984), filed with the Commission on March 8, 2016, and incorporated by reference herein.

    (11) Previously filed as Exhibit 4.10 to the Registrant’s Registration Statement on Form S-8 (File No. 333-210586), filed with the Commission on April 4, 2016, and incorporated by reference herein.

    (12) Previously filed as Exhibit 4.7 to the Registrant’s Registration Statement on Form S-8 (File No. 333-210586), filed with the Commission on April 4, 2016, and incorporated by reference herein.

    (13) Previously filed as Exhibit 10.7 to the Registrant’s Current Report on Form 8-K (File No. 333-198168), filed with the Commission on December 10, 2015, and incorporated by reference herein.

    (14) Previously filed as Exhibit 10.8 to the Registrant’s Current Report on Form 8-K (File No. 333-198168), filed with the Commission on December 10, 2015, and incorporated by reference herein.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Germantown, State of Maryland, on this 20th day of May, 2026.

     

    SENSEONICS HOLDINGS, INC.  
       
    By: /s/ Timothy T. Goodnow, Ph.D.  
      Timothy T. Goodnow  
      President and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Timothy T. Goodnow and Rick Sullivan, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Timothy T. Goodnow. Ph.D.   President, Chief Executive Officer and Director (Principal Executive Officer)   May 20, 2026
    Timothy T. Goodnow      
             
    /s/ Rick Sullivan   Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)   May 20, 2026
    Rick Sullivan      
             
    /s/ Stephen P. DeFalco   Chairman of the Board of Directors   May 20, 2026
    Stephen P. DeFalco        
             
    /s/ Steven Edelman, M.D.   Director   May 20, 2026
    Steven Edelman        
             
    /s/ Brian Hansen   Director and Chief Commercial Officer   May 20, 2026
    Brian Hansen        
             
    /s/ Edward J. Fiorentino   Director   May 20, 2026
    Edward J. Fiorentino        
             
    /s/ Francine Kaufman, M.D.   Director and Chief Medical Officer   May 20, 2026
    Francine Kaufman        
             
    /s/ Sharon Larkin   Director   May 20, 2026
    Sharon Larkin        
             
    /s/ Douglas S. Prince   Director   May 20, 2026
    Douglas S. Prince        
             
    /s/ Douglas A. Roeder   Director   May 20, 2026
    Douglas A. Roeder        

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    10/21/2025$9.00Hold
    Stifel
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roeder Douglas A bought $126,134 worth of shares (22,686 units at $5.56), increasing direct ownership by 19% to 144,635 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/13/26 4:15:05 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A bought $100,275 worth of shares (17,500 units at $5.73), increasing direct ownership by 17% to 119,731 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:45 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    President and CEO Goodnow Timothy T bought $99,733 worth of shares (17,225 units at $5.79), increasing direct ownership by 3% to 651,243 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    SEC Filings

    View All

    SEC Form SD filed by Senseonics Holdings Inc.

    SD - Senseonics Holdings, Inc. (0001616543) (Filer)

    6/1/26 5:07:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Senseonics Holdings Inc.

    S-8 - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:51:58 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:29:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

    GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. Senseonics will be hosting an analyst event to discuss the Eversense 365 platform, as well as an oral presentation on the ADA program discussing real world evidence of the world's first and only one year CGM system. Analyst Event DetailsSenseonics

    6/1/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

    Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update

    5/7/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of c

    5/4/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:42:42 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    GC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:41:33 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:40:28 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will hold a conference call to review the Company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseon

    5/1/26 9:10:31 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

    Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite

    1/12/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care